- Drug Pipelines
- May 2018
- 79 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- April 2018
United States
From €7779EUR$7,995USD£6,664GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21406EUR$22,000USD£18,337GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- July 2023
- 87 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- April 2023
- 97 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Drug Pipelines
- November 2019
- 58 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- February 2019
- 202 Pages
Global
From €5225EUR$5,370USD£4,476GBP
Tocilizumab is a monoclonal antibody used to treat immune disorders, such as rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and giant cell arteritis. It works by blocking the action of interleukin-6, a protein that plays a role in inflammation. It is administered intravenously or subcutaneously. Common side effects include upper respiratory tract infections, headache, and nausea.
Tocilizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2010. It is used to treat a variety of immune disorders, and is often used in combination with other drugs. It has been found to be effective in reducing inflammation and improving symptoms in patients with rheumatoid arthritis and other immune disorders.
Several companies are involved in the Tocilizumab market, including Roche, Chugai Pharmaceuticals, and Eli Lilly. These companies manufacture and distribute the drug, as well as provide support services to healthcare providers and patients. Show Less Read more